Graham F. Smith.

Graham F. Smith.

Auto-generated profile, based on publicly available information

Graham F. Smith.

AstraZeneca, Data Science and AI, Clinical Pharmacology and Safety Sciences, R&D, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
JSJoerg Schlingemann
Joerg Schlingemann
MBMichael J. Burns
Michael J. Burns
DPDavid J. Ponting
David J. Ponting
CACarolina Martins Avila
Carolina Martins Avila
NRNaiffer E. Romero
Naiffer E. Romero
AWAndrzej Wilk
Andrzej Wilk
This article reports the outcome of an in silico analysis of more than 12,000 small molecule drugs and drug impurities, identifying the nitrosatable structures, assessing their potential to form nitrosamines under relevant conditions and the challenges to determine compound-specific AIs based on data available or read-across approaches for these nitrosamines and their acceptance by health authorities. Our data indicate that the presence of nitrosamines in pharmaceuticals is likely more prevalent than originally expected. In total, 40.4 % of the analyzed APIs and 29.6 % of the API impurities are potential nitrosamine precursors. Most structures identified through our workflow could form complex API-related nitrosamines, so-called nitrosamine drug substance related impurities (NDSRIs), although we also found structures that could release the well-known small and potent nitrosamines NDMA, NDEA, and others. Due to common structural motifs including secondary or tertiary amine moieties, whole essential drug classes such as beta blockers and ACE inhibitors are at risk. To avoid the risk of drug shortages or even the complete loss of therapeutic options, it will be essential that the well-established ICH M7 principles remain applicable for nitrosamines and that that the industry and regulatory authorities keep an open communication not only about the science but also to make sure there is a good balance between risk and benefit to patients.

7 February 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
NRNoreen F. Rizvi
Noreen F. Rizvi
JHJohn A. Howe
John A. Howe
ANAli Nahvi
Ali Nahvi
DKDaniel J. Klein
Daniel J. Klein
TFThierry O. Fischmann
Thierry O. Fischmann
ENElliott B. Nickbarg
Elliott B. Nickbarg

1 January 2011
Verified
Book Chapter
Closed access
GSGraham F. Smith
Graham F. Smith

26 July 2023 in Organic Process Research & Development
Verified
Journal Article
Open access
RNRaphael Nudelman
Raphael Nudelman
GKGrace Kocks
Grace Kocks
BMBruno Mouton
Bruno Mouton
DPDavid J. Ponting
David J. Ponting
JSJoerg Schlingemann
Joerg Schlingemann
AWAnne-Laure Werner
Anne-Laure Werner

12 April 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
OOOlga Obrezanova
Olga Obrezanova
AMAnton Martinsson
Anton Martinsson
TWTom Whitehead
Tom Whitehead
SMSamar Mahmoud
Samar Mahmoud
ABAndreas Bender
Andreas Bender
NGNigel Greene
Nigel Greene

1 December 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NRNoreen F. Rizvi
Noreen F. Rizvi
GSGraham F. Smith
Graham F. Smith